The arrival of Mounjaro (tirzepatide) in the UK has been eagerly anticipated by patients and clinicians alike. Here's a comprehensive look at the regulatory timeline and current availability.
MHRA Approval
The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for tirzepatide in the UK, following a thorough review of safety and efficacy data from the extensive SURPASS and SURMOUNT clinical trial programmes. This approval covered its use for both type 2 diabetes and chronic weight management in eligible adults.
NICE Assessment
The National Institute for Health and Care Excellence (NICE) plays a crucial role in determining which treatments the NHS funds in England and Wales. NICE has assessed tirzepatide through its technology appraisal process, evaluating its cost-effectiveness relative to existing treatments. For type 2 diabetes, NICE guidance has been positive, enabling NHS prescribing. The weight management indication has also been reviewed, with NICE recognising the significant clinical benefits demonstrated in trials.
NHS Availability
Following NICE approval, NHS England began the process of making tirzepatide available through the health service. In practice, NHS access can vary by region and is subject to:
- Local commissioning decisions by Integrated Care Boards (ICBs)
- Specialist weight management service referrals
- Existing prescribing guidelines within each NHS Trust
Patients with type 2 diabetes have generally found it easier to access Mounjaro on the NHS than those seeking it purely for weight management.
Private Prescription Availability
Many UK patients have accessed Mounjaro ahead of broader NHS rollout through private prescriptions. Numerous registered online pharmacies now offer clinical consultations and Mounjaro prescriptions, with the medication delivered directly to your door. This route is typically faster but comes at an out-of-pocket cost.
Supply Considerations
Like many GLP-1 medications, Mounjaro has experienced periods of high demand that have occasionally outstripped supply. Eli Lilly has worked to increase manufacturing capacity, and availability has improved. However, some doses may periodically be harder to source than others. Checking multiple pharmacies through MedsLens can help you find stock at competitive prices.
Scotland, Wales, and Northern Ireland
Approval processes differ slightly across the devolved nations. The Scottish Medicines Consortium (SMC) conducts its own assessments for Scotland, while the All Wales Medicines Strategy Group (AWMSG) advises in Wales. Northern Ireland generally follows NICE recommendations. Availability timelines may differ by a few months.
Looking Ahead
As supply stabilises and NHS pathways become more established, Mounjaro is expected to become increasingly accessible to UK patients who meet the clinical criteria. Staying informed about pricing and availability through comparison tools like MedsLens ensures you get the best value.